LIXT vs LRMR

Lixte Biotechnology Holdings, I vs Larimar Therapeutics, Inc. — Valuation Comparison 2026

LIXT

Biotechnology
Lixte Biotechnology Holdings, I
Quality
4.2
out of 10
Value Trap
6
SAFE
Price
$5.99
Last close
Models
7/13
Active
VS

LRMR

Biotechnology
Larimar Therapeutics, Inc.
Quality
4.8
out of 10
Value Trap
36
LOW
Price
$3.49
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType LIXT Fair ValueLIXT Upside LRMR Fair ValueLRMR Upside
Bayesian DCF Intrinsic $1.66 -72.3% $1.86 -46.7%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.06 -98.1% $1.82 -47.7%
Dynamic NAV Asset-Based $0.71 -88.2% $2.92 -16.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for LIXT vs LRMR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

LIXT vs LRMR — Which Stock Is More Undervalued?

LRMR scores higher with a 4.8/10 quality rating vs LIXT's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Lixte Biotechnology Holdings, I (LIXT) and Larimar Therapeutics, Inc. (LRMR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

LIXT currently trades at $5.99 with a QOC of 4.2/10, while LRMR trades at $3.49 with a QOC of 4.8/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).